23例室管膜下巨细胞星形细胞瘤的治疗评价
23례실관막하거세포성형세포류적치료평개
Therapeutic review of 23 subependymal giant-cell astrocytoma
  • 万方数据
    中国医师进修杂志 중국의사진수잡지
    CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
    2009年 23期 18-21 ,共4页

    韩利江%赵继宗%马振宇%林松%赵元立%袁葛%季楠%田永吉%任同%张东%孙振荣%肖新如%唐凯%朴明学%李学记%刘海%叶迅%陈晓霖

    한리강%조계종%마진우%림송%조원립%원갈%계남%전영길%임동%장동%손진영%초신여%당개%박명학%리학기%류해%협신%진효림

    室管膜下巨细胞星形细胞瘤%治疗%评估%预后 室管膜下巨細胞星形細胞瘤%治療%評估%預後
    실관막하거세포성형세포류%치료%평고%예후
    Subependymal giant-cell astreeytoma%Treatment%Estimate%Prognosis
    目的 分析评价室管膜下巨细胞星形细胞瘤(SEGCA)的治疗.方法 回顾性研究1995年2月至2008年2月收治的经病理证实的SEGCA 23例患者的治疗和预后.结果 全切16例,近全切7例,辅助放疗17例.随访1～155个月,平均53个月,肿瘤复发1例,癫痫完全消失占17.6%(3/17),部分改善占47.1%(8/17).所有病例均存活.结论 手术全切是关键,放疗的意义有待确定.SEGCA总体预后较好.
    목적 분석평개실관막하거세포성형세포류(SEGCA)적치료.방법 회고성연구1995년2월지2008년2월수치적경병리증실적SEGCA 23례환자적치료화예후.결과 전절16례,근전절7례,보조방료17례.수방1～155개월,평균53개월,종류복발1례,전간완전소실점17.6%(3/17),부분개선점47.1%(8/17).소유병례균존활.결론 수술전절시관건,방료적의의유대학정.SEGCA총체예후교호.
    Objective To analyze and estimate, the treatment of patients with histologically confirmed subependymal giant-cell astroeytoma (SEGCA). Methods The data from 23 patients with SEG-CA who were diagnosed between February 1995 and February 2008 were retrospectively evaluated. Various combinations of surgery and radiotherapy had been used for treatment. Results Total resection was 16 cases, subtotal resection was 7 cases, radiotherapy was 17 cases. The average follow-up time was 53 months.One postoperative SEGCA recurrence. Epilepsy was totally disappeared in 17.6% (3/17), partly disappeared in 47.1%(8/17). All cases survived. Conclusions The key of treatment is total resection. The significance of radiotherapy is not sure. The overall prognosis of SEGCA is favorable.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문